IBRX ImmunityBio Covid19 Vaccine + pipeline interessante

[ilovepablo]

Visto che J&J, Astrazeneca & co non stanno dando i risultati sperati e che la vaccinazione di massa è sempre più l'unico modo chiaro per uscire dalla pandemia, mi sono messo a fare una ricerca dei papabili candidati per lo sviluppo di altri vaccini nel breve periodo.

I titoli che mi sono sembrati più interessanti sono GSK, CVAC, DVAX e IBRX.

IBRX ImmunityBio mi sembra in assoluto il più promettente dato che hanno in cantiere diversi sviluppi in fase avanzata del trial (fase 2 e fase 3)

Come si può vedere da qui: Pipeline - ImmunityBio

Hanno recentemente fatto un merger con NK che è stato accolto positivamente dal mercato, ma poi è stata massacrata come tante altre nelle ultime settimane. Hanno 75M di cassa e ne bruciano 100 all'anno per la ricerca. Al momento no revenue, ma hanno tanti progetti in fase avanzata.

Quindi rischio concreto di adc e diluizioni per finanziare la ricerca, ma possibilità elevate di successo nel lungo periodo.

Se qualcuno più esperto di me ha voglia di darci un'occhiata e darmi il suo parere ve ne sarei grato.

 

[ilovepablo]

Ottimi risultati dagli studi sul vaccino anti-covid19 contro tutte le varianti.

Announcing preliminary Phase 1 data, ImmunityBio (NASDAQ:IBRX) has highlighted the potential of its experimental dual antigen hAd5 S + N vaccine against COVID-19 to provide long-term protection as well as immunity against the new coronavirus variants.

A single subcutaneous injection of the shot in healthy subjects has generated T cells that are reactive to the spike (NYSE:S) and nucleocapsid (NYSE:N) protein antigens delivered by the vaccine, the company said.

By day 21, T cell responses against both S and N antigens reached levels have reached ten times higher than the pre-vaccination levels. The mean T cell levels in those inoculated with the vaccine were equivalent to patients recovered from the COVID-19 infection.

However, the data are yet to be peer-reviewed and are published in the preprint server medRxiv.

Targeting the S protein of the virus, the current generation of vaccines are less effective against coronavirus variants, noted, Patrick Soon-Shiong, CEO of ImmunityBio.

“Our goal is to develop the second-generation COVID-19 vaccine which is room temperature stable, can be self-administered orally, and generates both antibody and long-term T cell immunity,” Dr. Soon-Shiong added.

Phase 1b trials are ongoing to find the best combination of subcutaneous, oral, or sublingual forms of hAd5 S+N to achieve maximum protection.
The T cell-based, viral vector vaccine candidate generated no serious adverse events, according to interim data from a Phase 1 study involving 12 subjects.

 

[ilovepablo]

Ieri ha chiuso a quasi +9%...

A nessuno interessa questa stock?

 

[Biotechfun]

Ieri ha chiuso a quasi +9%...

A nessuno interessa questa stock?

Pablo occhio che ieri han rimbalzato un pò tutte le biotech.

 

[ilovepablo]

Pablo occhio che ieri han rimbalzato un pò tutte le biotech.

Sisì chiaro, però come detto mi sembra avere tanta carne al fuoco

 

[ilovepablo]

ImmunityBio shares rise ahead of anktiva ASCO data
May 20, 2021 9:39 AM ETImmunityBio, Inc. (IBRX)By: Aakash Babu, SA News Editor1 Comment
ImmunityBio (IBRX +1.7%) talks up upcoming poster presentation highlighting its chemotherapy free regimen of interleukin-15 (IL-15) superagonist anktiva in patients who had relapsed from checkpoint inhibitors, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place next month.
The Phase 2 study details data highlighting the safety and clinical benefit of adding anktiva to checkpoint inhibitor therapy in second-line or greater treatment regimens in multiple cancer types.
121 evaluable patients to date with preliminary data demonstrating 68% (82 out of 121) disease control (partial response and stable disease >6 weeks).
Anktiva exhibits a favorable toxicity profile in combination with several different checkpoint inhibitors in second-line or greater settings, across a variety of tumor types.
Treatment-related serious adverse events ((SAEs)) were seen in 8% of study participants.
#ASCO21


Buone notizie!

 

[ilovepablo]

Sempre più interessante.

Incrementato @ 6.05

 

[ilovepablo]

ImmunityBio rises after data from late-stage bladder cancer trial for Anktiva


In a cohort A consisting of 83 patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), 59 (71%) had a complete response with a median duration of response at 24.1 months.

That exceeded the historical response rates of 41% and 18% for FDA-approved therapies pembrolizumab known commercially as Keytruda, and chemotherapy agent, valrubicin, respectively.

In the papillary disease arm of the study (Cohort B), 57% and 53% of patients were free from disease at 12 and 18 months, respectively.

In terms of the safety profile, none of the patients in the cohorts experienced treatment-related SAEs, immune-related AE, and 0% grade 4 and 5 AE, according to the company.

ImmunityBio rises after data from late-stage bladder cancer trial for Anktiva | Seeking Alpha

Ottime news!

Nessuno dentro?

 

[ilovepablo]

Chiusura odierna a +20%

Era da un pezzo che non si vedevano numeri così